Houston innovator: 3 reasons you should incorporate estate planning to your company benefits

guest column

Why you should be offering your employees estate and legacy planning tools. Photo courtesy of The Postage

As priorities for employees have shifted as part of the Great Resignation the need for non-traditional benefits has continued to arise. Employees are expecting their personal and family wellness to be at the core of what their employers are offering. This is a big consideration when deciding to stay or leave a company. While HR professionals and employers are realizing they need to re-evaluate their benefits and how they keep top talent, there’s one key benefit that is typically missed that is a life necessity for all, estate and legacy planning.

Given today’s uber competitive talent market, there’s an opportunity for companies to embrace new benefits that go beyond the typical and support vital needs, such as financial wellness and estate planning. Taking the next step by providing and connecting employees with the right resources can make all the difference. Estate and legacy planning goes beyond creating a will, it’s about end to end care of life and legacy. It helps transition wealth and wisdom across generations. It handles your affairs, finances, your digital assets, protects your children and pets, and ensures your wishes are carried out if you are temporarily unavailable or permanently incapable of handling them. It’s as critical and as necessary as insurance yet is not typically included as a key employee benefit.

Why should you add estate and legacy planning as part of your employee benefits? Here’s the top three reasons to consider:

1. Create value for your employees and their families

Financial wellness and security are the utmost important for employees. In fact, it’s one of the most-valued benefits, based on a recent survey Morgan Stanley found that 90 percent of employees want their company to prioritize financial benefits. Are you going to be one of the 95 percent of HR executives that plan to do so? If so, there are multiple ways that a company can help its employees to build wealth and protect their financial security through traditional benefits such as retirement savings plans, health insurance, voluntary life, and disability insurance, and more. But additional benefits like estate and legacy planning should be a part of this assortment of benefits that support protecting employees and their families’ finances - by helping them build and protect their financial and personal legacies.

Employers can show that they value and support their employee’s financial success and security by providing tools and resources that make it simple to handle these historically daunting tasks and keep them organized throughout life, which allows employees to have peace of mind for their families’ future, financial and beyond.

2. Stand out among your competitors

Most employers do not provide legacy and estate planning services. Only 12 percent of employers provide these types of benefits, yet over 72 percent of those who are not offered estate planning services by their employer, would be interested in using them if offered. That’s a huge percentage of your employee population that would benefit from this service while differentiating you from other employers and provide an opportunity for your company to show just how much you value your employees’ futures.

3. Show you care about your employees

More people have begun to self-reflect on what is truly important to them as a part of the Great Resignation. Now, employee desires have evolved beyond a high salary with decent benefits. Employees want to feel valued beyond the work they do, and even further than that, they need an environment where their career, their loved ones, and their own being is supported. These psychological needs are translating into demands for companies to provide more thoughtful employee benefits packages.

A study conducted by Morgan Stanley shows how perceptions of employees and HR executives alike have transformed, with 9 in 10 HR executives saying their company needs to do a better job helping employees understand how to maximize their financial benefits. Proving to your employees that you care about them beyond the ‘now’–beyond simply providing short-term benefits that exclusively affect them in the present day–leverages your company’s commitment to caring for your workers.

For people that struggle with organizing their property and wealth, estate planning can help visualize their total net worth. However, benefits that not only anticipate employees’ future financial needs but also organize their family network will drive continual engagement within your company and prove genuine care for your workers. For example, The Postage helps people plan their legacy. On top of estate planning, customers also have the ability to store and document important life events and memories, or even utilize our message planning feature where they can send timely notes to their family at a future date.

Employees want to feel valued beyond their work and taking the steps to help them build physical and financial legacies for both themselves and their loved ones will put your company one step ahead of everyone else. It is time for estate planning to join the conversation for employee benefits packages and helping employees proactively plan their future could be the cornerstone of attracting and retaining diverse talent.

------

Emily Cisek is the founder and CEO of The Postage, a tech-enabled, easy-to-use estate planning tool.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings